A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441
Recruiting
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +10 locations
Conditions: Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Register for Updates
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
NCT06963710
Recruiting
This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/25/2025
Locations: Aligos Investigational Site, Chandler, Arizona +6 locations
Conditions: Chronic Hepatitis B Infection
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Anchorage, Alaska +259 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587
Recruiting
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +20 locations
Conditions: Solid Tumor
Register for Updates
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
NCT06765161
Recruiting
This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/25/2025
Locations: Clinique Neuro-Outaouais, Gatineau, Quebec
Conditions: Myasthaenia Gravis
Register for Updates
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Clinical Trial Site, San Diego, California +7 locations
Conditions: Early-Onset Alzheimer Disease
Register for Updates
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
NCT03816319
Recruiting
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Moffitt Cancer Center, Tampa, Florida +3 locations
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona +117 locations
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates
Product Surveillance Registry
NCT01524276
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
ALL
Ages:
All
Trial Updated:
07/24/2025
Locations: Not set, Birmingham, Alabama +381 locations
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Register for Updates
Feasibility and Acceptability of an E-learning Dialectical Behavior Therapy Skills Course
NCT07088939
Recruiting
Dialectical behavior therapy (DBT) is a comprehensive, third-wave psychological intervention designed for patients with complex and severe behavioral, emotional, and interpersonal dysfunction. DBT has since been adapted to shorter, briefer, "skills training" formats, which have been effective for a number of mild-to-moderate mental health conditions, including depression and anxiety. Moreover, internet-delivered formats of DBT (iDBT) have similarly started to build support for their effectivenes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Windsor, Windsor, Ontario
Conditions: Depression - Major Depressive Disorder, Anxiety, Depression, Stress, Mood Disorders
Register for Updates
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868
Recruiting
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Local Institution - 0303, Hot Springs, Arkansas +241 locations
Conditions: Breast Neoplasms
Register for Updates
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036
Recruiting
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed. These participants were no longer benefiting from standard medications and had no good treatment options. In that study, some participants who were treated with linvoseltamab had improvement of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of California Los Angeles (UCLA), Los Angeles, California +156 locations
Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Register for Updates